The online version of this article (https://doi.org/10.1186/s12884-018-1662-z) contains supplementary material, which is available to authorized users.
Cell-free DNA (cfDNA) screening has recently acquired tremendous attention, promising patients and healthcare providers a more accurate prenatal screen for aneuploidy than other current screening modalities. It is unclear how much knowledge regarding cfDNA screening obstetrical providers possess which has important implications for the quality and content of the informed consent patients receive.
A survey was designed to assess obstetrical provider knowledge and attitudes towards cfDNA screening and distributed online through the Society of Obstetricians & Gynecologists of Canada (SOGC). Chi-squared tests were used to detect differences in knowledge and attitudes between groups.
207 respondents completed the survey, composed of 60.6% Obstetricians/Gynecologists (OB/GYN), 15.4% Maternal Fetal Medicine (MFM) specialists, 16.5% General Practitioners (GP), and 7.5% Midwives (MW). MFM demonstrated a significant trend of being most knowledgeable about cfDNA screening followed by OB/GYN, GP, and lastly MW in almost all aspects of cfDNA screening. All groups demonstrated an overall positive attitude towards cfDNA screening; however, OB/GYN and MFM demonstrated a significantly more positive attitude than GP and MW. Despite not yet being a diagnostic test, 19.4% of GP would offer termination of pregnancy immediately following a positive cfDNA screen result compared to none of the MFM and only few OB/GYN or MW.
We have demonstrated that different types of obstetrical providers possess varying amounts of knowledge regarding cfDNA screening with MFM currently having greater knowledge to all other groups. All obstetrical providers must have adequate prenatal screening understanding so that we can embrace the benefits of this novel and promising technology while protecting the integrity of the informed consent process.
Additional file 1: Obstetrical Care Provider Survey. This file contains the sample survey which we sent to obstetrical care providers exploring their knowledge and attitudes towards cell-free DNA screening. This document includes both English and French versions (DOCX 119 kb)12884_2018_1662_MOESM1_ESM.docx
Rose NC, Mercer BM. Practice Bulletin No. 163: screening for fetal aneuploidy. Obstet Gynecol. 2016;127(5):e123–37.
Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012 Apr;206(4):322.e1–322322.e5.
Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, et al. Non-invasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012 Aug;207(2):137.e1–137137.e8.
GD Specialized Diagnostics. OHIP now covers payments for the Harmony (TM) Prenatal Test. Laval: Gamma-Dynacare 2014;2014 January 27.
BC PS. Non-Invasive Prenatal Testing - Funded NIPT for women at high risk: Provincial Health Services Authority; 2017 [Available from: http://www.perinatalservicesbc.ca/health-professionals/professional-resources/screening/prenatal-genetic/non-invasive-prenatal-testing-nipt.
OMY N, Yi H, SYS W, Sahota D, Ahmed S. Obstetric professionals' perceptions of non-invasive prenatal testing for down syndrome: clinical usefulness compared with existing tests and ethical implications. BMC Pregnancy Childbirth. 2017;17(1):285. CrossRef
Benn P, Borrell A, Chiu RW, Cuckle H, Dugoff L, Faas B, et al. position statement from the chromosome abnormality screening committee on behalf of the Board of the International Society for prenatal diagnosis. Prenat Diagn 2015 Aug;35(8):725–734.
- Obstetrical provider knowledge and attitudes towards cell–free DNA screening: results of a cross-sectional national survey
Wilson V. Chan
R. Douglas Wilson
- BioMed Central
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II